Articles related to ADJUVANT TREATMENT

Event-free survival was significantly longer in patients with resectable stage III or IV melanoma who received pembrolizumab both before and after surgery than in those who received adjuvant pembrolizumab alone. New toxic effects were not discovered.

An earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy showed that the addition of pembrolizumab to neoadjuvant chemotherapy resulted in a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery. The trial’s main findings on event-free survival have not been published.

The researchers tested whether a ctDNA-guided strategy could lower the need for adjuvant chemotherapy without increasing the risk of recurrence. Recurrence-free survival at 2 years was the main efficacy end objective. Adjuvant chemotherapy usage was a significant secondary end goal.

In this trial, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more in patients with high-risk muscle-invasive urothelial carcinoma who had had radical surgery.

In this multi-institutional study, AT significantly increased progression-free and overall survival in 430 patients with node-negative (N0) disease after NAT for localized pancreatic cancer (4.1 vs 2.1 and 5.3 vs 3.5 years, respectively). Patients who received neoadjuvant radiation had their overall survival benefit scaled back, while patients with perineural invasion saw an increase.

In patients with stage IIIB-D or IV melanoma, adjuvant nivolumab with ipilimumab did not increase recurrence-free survival compared to nivolumab monotherapy. Both treatment regimens’ safety and health-related quality of life were similar with earlier research.